Virginia hosted more than 3,400 clinical studies of new drugs in the last 13 years, with almost 50% of them involving chronic diseases, PhRMA said in a report. "Biopharmaceutical companies don't have a prominent bricks-and-mortar presence in many of the states, but we nevertheless have a profound impact on communities all over the country because of our clinical trials," PhRMA spokesman Jeff Trewhitt said. The report is part of an effort to show the health and economic impacts of biopharmaceutical companies' research funding.

Related Summaries